Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 8 ( August, 2022 ) > List of Articles


Thymosin α1 for COVID-19: Look before You Leap!

Citation Information : Thymosin α1 for COVID-19: Look before You Leap!. Indian J Crit Care Med 2022; 26 (8):892-893.

DOI: 10.5005/jp-journals-10071-24297

License: CC BY-NC 4.0

Published Online: 30-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


PDF Share
  1. Siddiqi HK, Mehra MR. COVID-19 illness in native and immuno-suppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405–407. DOI: 10.1016/j.healun. 2020.03.012.
  2. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19–Final report. N Engl J Med 2020;383(19):1813–1826. DOI: 10.1056/NEJMoa2007764.
  3. Strategic Advisory Group of Experts on Immunization (SAGE). [Accessed July 17, 2022].
  4. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 2022;386(15):1397–1408. DOI: 10.1056/NEJMoa2118542.
  5. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med 2022;386(6): 509–520. DOI: 10.1056/NEJMoa2116044.
  6. Mouffak S, Shubbar Q, Saleh E, El-Awady R. Recent advances in management of COVID-19: A review. Biomed Pharmacother 2021;143:112107. DOI: 10.1016/j.biopha.2021.112107.
  7. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436.
  8. Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: A meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med 2021;47(6):641–652. DOI: 10.1007/s00134-021-06416-z.
  9. Therapeutics and COVID-19: Living Guideline, 14 July 2022. Geneva: World Health Organization; 2022 (WHO/2019-nCoV/therapeutics/2022.4). Licence: CC BY-NC-SA 3.0 IGO.
  10. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2021;384(9):795–807. DOI: 10.1056/NEJMoa2031994.
  11. Garaci E. From thymus to cystic fibrosis: The amazing life of thymosin alpha 1. Expert Opin Biol Ther 2018;18(suppl 1):9–11. DOI: 10.1080/14712598.2018.1484447.
  12. Zatz MM, Oliver J, Samuels C, Skotnicki AB, Sztein MB, Goldstein AL. Thymosin increases production of T-cell growth factor by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1984;81(9):2882–2885. DOI: 10.1073/pnas.81.9.2882.
  13. Matteucci C, Minutolo A, Balestrieri E, Petrone V, Fanelli M, Malagnino V, et al. Thymosin alpha 1 mitigates cytokine storm in blood cells from Coronavirus disease 2019 patients. Open Forum Infect Dis 2021;8(1):ofaa588. DOI: 10.1093/ofid/ofaa588.
  14. Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, et al. Thymosin alpha 1 reduces the mortality of severe Coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin Infect Dis 2020;71(16):2150–2157. DOI: 10.1093/cid/ciaa630.
  15. Shetty A, Chandrakant NS, Darnule RA, Manjunath BG, Sathe P. A double-blind multicenter two-arm randomized placebo-controlled phase-III clinical study to evaluate the effectiveness and safety of thymosin α1 as an add-on treatment to existing standard of care treatment in moderate-to-severe COVID-19 Patients. Indian J Crit Care Med 2022;26(8):913–919.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.